Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

With X-Pure™, Rousselot Sets a New Gelatin Standard for In-body Applications


News provided by

Rousselot

17 May, 2018, 07:00 GMT

Share this article

Share toX

Share this article

Share toX

SON, Netherlands, May 17, 2018 /PRNewswire/ --

Rousselot, the world leading producer1 of gelatin and collagen peptides, today launches a new medical grade gelatin range, X-Pure™, with outstanding levels of purity for in-body applications.

This image opens in the lightbox
With X-Pure™, Rousselot Sets a New Gelatin Standard for In-body Applications (PRNewsfoto/Rousselot)

     (Photo: https://mma.prnewswire.com/media/690359/X_PURE_BIS.jpg )

Visitors at the Bio International Convention in Boston can find out more at booth #2838 from 4 - 7 June. As part of the event's partnering initiative, Rousselot experts will be available for meeting with interested collaborators throughout the event.

Gelatin, a widely used biomaterial for pharma and medical applications 

Designed by nature, with low allergenicity and fully compatible with the human body, gelatin has been Generally Recognized As Safe (GRAS) by the United States Food and Drug Administration (FDA). Its natural properties and high versatility make it the biomaterial of choice for the pharmaceutical and medical applications, including the most demanding ones such as in-body applications where undetectable or very low endotoxin levels are required.

Endotoxins may lead to immune response, even in minute quantities. For in-body applications, Rousselot has developed advanced gelatins with very low-endotoxin levels that can be used in wound healing, injectable fillers and high-end regenerative medicine applications.

The X-Pure range - An unrivalled offer for medical applications 

The latest innovation from Rousselot, X-Pure offers unrivalled levels of safety with endotoxin below 100, 20 or 10 Endotoxin Units per gram (EU/g) or even below LAL analysis detection limits2 if required. The range comprises of different grades of gelatin to exactly match the needs of final medical applications and bring a new level of safety in medical devices for in-body usage.

X-Pure for hemostatic medical devices: the world's lowest endotoxin levels 

Gelatin-based hemostats such as sponges, strips or powder are highly efficient in stopping blood flow. Fast acting, gelatin absorbs at least forty times its own weight. With X-Pure, Rousselot proposes four new gelatin solutions of porcine and bovine origin. With the X-Pure™ 10 P grade in particular, Rousselot launches an exceptionally safe acid porcine skin gelatin that exhibits outstanding foaming properties and unseen lows in endotoxin levels.

X-Pure for parenteral formulations: a highly pure, safe and consistent gelatin 

For parenteral formulations, Rousselot has developed X-Pure™ 10 HGP, a hydrolyzed gelatin with excellent stabilizing properties. As it is purified by a validated process, manufacturers also benefit from maximum quality consistency. X-Pure™ 10 HGP comes with less than 10 EU/g Endotoxin units, and is the safest choice for parenteral formulations.

X-Pure for regenerative medicine applications: a unique, global one-stop brand of purified gelatins 

Used in particular for tissue or stem cell bioengineering, or for the controlled delivery of biomolecules, gelatin mimics the extra-cellular-matrix closely and it is one of the most favorable biomaterials used today. However for most applications in the regenerative medicine field, biomaterials should exhibit a strict purity and safety profile. In the case of cell culture for example, endotoxins have been shown to have a negative effect on cell growth. To answer the needs of this fast growing and diverse market, Rousselot developed five grades of highly purified gelatins, each of them exhibiting different viscosities, gel strengths and endotoxin levels.

"We are extremely proud to bring the purest gelatins to the medical market and to highly sensitive medical applications. This outstanding, industry-leading product offers unique advantages to assure performance, quality and safety across these areas," comments Tanja Vervust, Global Quality Director, Rousselot. She adds "As the global leader in gelatin production and innovation with a strong R&D team and a world-class laboratory in Ghent, we're perfectly positioned to support our clients who want to benefit from our new product. We're looking forward to the Bio International Convention to partner with medical and pharma companies in need of safe and reliable biomaterials."

Rousselot X-Pure endotoxin levels are determined using Charles River LAL (Limulus Amebocyte lysate) assay, validated for our product. This method provides rapid and reliable results without animal testing and is US FDA compliant.

To find out more, visit X-Pure.com and meet our experts at booth #2838 at Bio International Convention in Boston from 4 - 7 June 2018. Rousselot's teams are available to support customers develop specific tailored advanced solutions and help them maximize the use and application of ultra-pure gelatin. 

Rousselot and Peptan are both brands of Darling Ingredients Inc. Rousselot is the global leader3 in gelatin and collagen peptides. Rousselot's wide range of collagen peptides are marketed under the Peptan brand. We work in partnership with our customers all over the world, delivering innovative and advanced ingredient solutions manufactured through state of the art operations. We help our customers achieve their goals, enabling them to create world class pharmaceutical, food and nutritional products to inspire and excite today's demanding consumers.

1 Global Industry Analysts, Inc, Gelatin a Global Strategic Business report, Nov 2016

2 These levels are determined by means of the Charles River LAL (Limulus Amebocyte lysate) assay, an FDA compliant method. 

3 Global Industry Analysts, Inc, Gelatin a Global Strategic Business report, Nov 2016

Modal title

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.